Q1 FY26-27: standalone loss of Rs 234 lakh, consolidated loss of Rs 682 lakh

Net loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹70.78

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+0.2% vs market

Pharmaceuticals peers, median of 167sector-0.4%+0.7% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.1+0.2-0.4+0.7

Next day

—+0.2—-0.4—

—+0.6—-0.5—

—-0.0—-1.4—

—+0.5—-0.9—

—+0.8—-0.4—

—+0.6—-0.9—

15d

—+1.3—+0.0—

—-1.4—-0.1—

—-0.6—-2.8—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sunil Healthcare board approved unaudited Q1 FY26-27 results ended 30 June 2026. Standalone PAT was a loss of Rs 234.21 lakhs with negative EPS of Rs 2.28. Consolidated PAT showed a loss of Rs 682.01 lakhs with negative EPS of Rs 6.65. Standalone revenue from operations stood at Rs 1,898.59 lakhs. Auditor Singhi and Co issued an unmodified review report. AGM scheduled for September 2026.

Likely market impact

Losses in both standalone and consolidated results point to continued profitability pressure. Negative EPS may weigh on investor sentiment near term.